TFDP2-PDK3 metabolic signaling drove nasopharyngeal carcinoma radioresistance
TFDP2 activated PDK3, shifted nasopharyngeal carcinoma cells toward glycolysis, and reduced radiation response in cellular and xenograft models.
TFDP2 activated PDK3, shifted nasopharyngeal carcinoma cells toward glycolysis, and reduced radiation response in cellular and xenograft models.
Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.
Tomotherapy improved target coverage and reduced bilateral lung exposure compared with VMAT and fixed-field IMRT in 20 whole-pleural irradiation cases.
Early-treatment ventilation direction persisted to treatment completion in most photon- and proton-treated patients, with the prediction model explaining 89% of variation.
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
Preclinical lung studies support normal-tissue sparing, but uncertain biological thresholds, dose conformity, and respiratory motion still prevent clinical implementation.
An Eclipse-based tool reduced lattice plan evaluation from 15.4 to 2.0 minutes while maintaining close agreement with manual measurements.
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Positive margins more than doubled mortality risk and quadrupled local recurrence risk in a meta-analysis of 2,438 post-radiation sarcoma patients.
Preoperative SRS/FSRT completed local therapy 22.5 days sooner than postoperative treatment, with similar 30-day morbidity; oncologic outcomes remain pending.
A 30–70% gating window reduced planning target volume by 34% and mean lung dose by 0.75 Gy without compromising coverage.
USP15 stabilized FIS1, suppressed oxidative phosphorylation, and increased radiosensitivity; metformin restored radiation response in USP15-low bladder cancer models.
Leave-one-cancer-type-out genomic scores remained associated with progression in five of eight cancers, with the largest performance gain in cervical cancer.
AI-assisted planning cut average planning time from about two hours to 30 minutes, but three of 12 plans required manual hotspot correction.
A phantom-derived model predicted SCART central target radius with R² values of 0.991–0.999, but clinical validation remains absent.